These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36578217)

  • 1. HDAC6 regulates human erythroid differentiation through modulation of JAK2 signalling.
    Vong P; Messaoudi K; Jankovsky N; Gomilla C; Demont Y; Caulier A; Jedraszak G; Demagny J; Djordjevic S; Boyer T; Marolleau JP; Rochette J; Ouled-Haddou H; Garçon L
    J Cell Mol Med; 2023 Jan; 27(2):174-188. PubMed ID: 36578217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
    Laino AS; Betts BC; Veerapathran A; Dolgalev I; Sarnaik A; Quayle SN; Jones SS; Weber JS; Woods DM
    J Immunother Cancer; 2019 Feb; 7(1):33. PubMed ID: 30728070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.
    Tong W; Zhang J; Lodish HF
    Blood; 2005 Jun; 105(12):4604-12. PubMed ID: 15705783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
    Wang F; Zhong BW; Zhao ZR
    J Biol Regul Homeost Agents; 2018; 32(4):851-858. PubMed ID: 30043566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
    Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
    Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation.
    Chuang MJ; Wu ST; Tang SH; Lai XM; Lai HC; Hsu KH; Sun KH; Sun GH; Chang SY; Yu DS; Hsiao PW; Huang SM; Cha TL
    PLoS One; 2013; 8(9):e73401. PubMed ID: 24023871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
    Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
    J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
    Dasmahapatra G; Patel H; Friedberg J; Quayle SN; Jones SS; Grant S
    Mol Cancer Ther; 2014 Dec; 13(12):2886-97. PubMed ID: 25239935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase 6 (HDAC6) promotes the pro-survival activity of 14-3-3ζ via deacetylation of lysines within the 14-3-3ζ binding pocket.
    Mortenson JB; Heppler LN; Banks CJ; Weerasekara VK; Whited MD; Piccolo SR; Johnson WE; Thompson JW; Andersen JL
    J Biol Chem; 2015 May; 290(20):12487-96. PubMed ID: 25770209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
    Beyer M; Kiweler N; Mahboobi S; Krämer OH
    Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
    Santo L; Hideshima T; Kung AL; Tseng JC; Tamang D; Yang M; Jarpe M; van Duzer JH; Mazitschek R; Ogier WC; Cirstea D; Rodig S; Eda H; Scullen T; Canavese M; Bradner J; Anderson KC; Jones SS; Raje N
    Blood; 2012 Mar; 119(11):2579-89. PubMed ID: 22262760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
    Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
    Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of HDAC6 attenuates LPS-induced inflammation in macrophages by regulating oxidative stress and suppressing the TLR4-MAPK/NF-κB pathways.
    Zhang WB; Yang F; Wang Y; Jiao FZ; Zhang HY; Wang LW; Gong ZJ
    Biomed Pharmacother; 2019 Sep; 117():109166. PubMed ID: 31255993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase 2 is required for chromatin condensation and subsequent enucleation of cultured mouse fetal erythroblasts.
    Ji P; Yeh V; Ramirez T; Murata-Hori M; Lodish HF
    Haematologica; 2010 Dec; 95(12):2013-21. PubMed ID: 20823130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation.
    Tsuji G; Okiyama N; Villarroel VA; Katz SI
    J Allergy Clin Immunol; 2015 May; 135(5):1228-39. PubMed ID: 25458911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase 6 inhibition mitigates renal fibrosis by suppressing TGF-β and EGFR signaling pathways in obstructive nephropathy.
    Chen X; Yu C; Hou X; Li J; Li T; Qiu A; Liu N; Zhuang S
    Am J Physiol Renal Physiol; 2020 Dec; 319(6):F1003-F1014. PubMed ID: 33103445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability.
    Jochems J; Boulden J; Lee BG; Blendy JA; Jarpe M; Mazitschek R; Van Duzer JH; Jones S; Berton O
    Neuropsychopharmacology; 2014 Jan; 39(2):389-400. PubMed ID: 23954848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.
    Shi J; Yuan B; Hu W; Lodish H
    Exp Hematol; 2016 Nov; 44(11):1044-1058.e5. PubMed ID: 27473563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC8-Selective Inhibition by PCI-34051 Enhances the Anticancer Effects of ACY-241 in Ovarian Cancer Cells.
    Kim JY; Han SY; Yoo J; Kim GW; Jeon YH; Lee SW; Park J; Kwon SH
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.